Barclays initiated coverage of Eli Lilly (LLY) with an Overweight rating and $1,350 price target The firm sees GLP-1 weight loss treatments as a “durable structural shift.” Eli Lilly is likely to remain the market share leader in obesity, the analyst tells investors in a research note. Barclays believes the shares are deserving of a premium valuation.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly announces long-term data on Omvoh in Crohn’s disease
- Eli Lilly Pushes Into Opioid Use Disorder With New Brenipatide Phase 2 Trial
- FDA to begin requiring on clinical trial
- FDA to begin requiring one clinical trial in drug approvals
- Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories!